Nektar Therapeutics Files 8-K with Material Agreement
Ticker: NKTR · Form: 8-K · Filed: Jul 1, 2025 · CIK: 906709
| Field | Detail |
|---|---|
| Company | Nektar Therapeutics (NKTR) |
| Form Type | 8-K |
| Filed Date | Jul 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, corporate-event
Related Tickers: NKTR
TL;DR
Nektar (NKTR) signed a big deal on 6/30, filed an 8-K.
AI Summary
On June 30, 2025, Nektar Therapeutics entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. Nektar Therapeutics, formerly Inhale Therapeutic Systems Inc., is incorporated in Delaware and headquartered in San Francisco, California.
Why It Matters
This 8-K filing indicates a significant new agreement for Nektar Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the nature of this agreement is not detailed in the provided text.
Key Numbers
- 0-24006 — Commission File Number (Nektar Therapeutics' SEC file number)
- 94-3134940 — IRS Employer Identification No. (Nektar Therapeutics' EIN)
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- Inhale Therapeutic Systems Inc. (company) — Former company name
- June 30, 2025 (date) — Date of earliest event reported
- 455 Mission Bay Boulevard South (address) — Principal Executive Offices
- San Francisco, California 94158 (address) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Nektar Therapeutics on June 30, 2025?
The provided text does not specify the details of the material definitive agreement.
What are the specific 'Other Events' reported by Nektar Therapeutics in this 8-K filing?
The filing mentions 'Other Events' but does not provide specific details in the excerpt.
When was Nektar Therapeutics previously known as Inhale Therapeutic Systems Inc.?
The filing indicates a date of name change to Inhale Therapeutic Systems Inc. in 19980723.
What is Nektar Therapeutics' principal executive office address?
Nektar Therapeutics' principal executive office is located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
What is the fiscal year end for Nektar Therapeutics?
Nektar Therapeutics' fiscal year ends on December 31 (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 1, 2025 regarding NEKTAR THERAPEUTICS (NKTR).